tradingkey.logo

Anteris Technologies Global Corp

AVR
View Detailed Chart
5.490USD
+0.270+5.17%
Close 02/06, 16:00ETQuotes delayed by 15 min
197.98MMarket Cap
LossP/E TTM

Anteris Technologies Global Corp

5.490
+0.270+5.17%
Intraday
1m
30m
1h
D
W
M
D

Today

+5.17%

5 Days

-8.04%

1 Month

+10.69%

6 Months

+44.47%

Year to Date

+10.02%

1 Year

-11.31%

View Detailed Chart

Key Insights

Anteris Technologies Global Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 98 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.00.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Anteris Technologies Global Corp's Score

Industry at a Glance

Industry Ranking
98 / 205
Overall Ranking
261 / 4521
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Anteris Technologies Global Corp Highlights

StrengthsRisks
Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.70M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.70M.
Fairly Valued
The company’s latest PE is -2.35, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 25.19M shares, increasing 5.38% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 2.04K shares of this stock.

Analyst Rating

Based on 4 analysts
Buy
Current Rating
15.000
Target Price
+187.36%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Anteris Technologies Global Corp News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Anteris Technologies Global Corp Info

Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
Ticker SymbolAVR
CompanyAnteris Technologies Global Corp
CEOPaterson (Wayne G)
Websitehttps://anteristech.com/
KeyAI